Correlation analysis of plasma YAP level with stroke prognostic factors and post-stroke inflammation

doi:10.3969/j.issn.1006-7795.2024.06.017

Abstract

Abstract: Objective This study aims to investigate the relationship of peripheral yes-associated protein (YAP) level in patients with acute ischemic stroke (AIS) with prognostic influencing factors and inflammatory indicators. Methods AIS patients admitted to Xuanwu Hospital of Capital Medical University from November 2018 to May 2019 were enrolled in this study. Expression levels of YAP and inflammatory markers in plasma were detected, and the clinical data and 3-month prognostic data of the patients were collected by experienced neurologists. According to the 3-month modified Rankin Scale (mRS) score, the patients were divided into good outcome group (mRS≤2, n=92) and poor outcome group (mRS>2, n=67). Multivariate Logistic regression analysis was used to identify independent risk factors related to AIS prognosis. Furthermore, Spearman correlation analysis and partial correlation analysis were conducted to explore the relationship of YAP concentration with these prognostic influencing factors and inflammatory indicators. Results Compared with the good outcome group, the poor outcome group exhibited significantly higher white blood cell counts, neutrophil counts, and neutrophil-lymphocyte ratios (NLR), along with significantly lower lymphocyte counts (P<0.05). Logistic regression results indicated that older age (OR=1.04, P=0.013), diabetes mellitus (OR=3.87, P=0.004), and higher admission National Institutes of Health Stroke Scale (NIHSS) scores (OR=1.36, P<0.001) are risk factors for prognosis. Correlation analysis showed that plasma YAP levels were positively correlated with lymphocyte counts (r=0.22, P=0.006), IL-1β (r=0.418, P<0.001), IL-2 (r=0.310, P<0.001), IL-5 (r=0.417, P<0.001), and IL-10 (r=0.189, P=0.017), while being negatively correlated with neutrophil counts (r=－0.17, P=0.027), NLR (r=－0.24, P=0.002), IL-2R (r=－0.259, P<0.001), IL-16 (r=－0.334, P<0.001), and (hepatocyte growth factor, HGF) (r=－0.317, P<0.001). Partial correlation analysis indicated that the correlation between YAP protein levels and IL-2, IL-16, and HGF was not affected by other variables (P<0.05). Conclusions There is a significant correlation between plasma YAP levels and various inflammatory indicators, suggesting that YAP may be involved in the regulation of inflammatory response after stroke.

Key words: acute ischemic stroke, yes-associated protein, inflammatory marker

CLC Number:

R743.3

Shen Tong, Li Fangfang, Fan Junfen, Luo Yumin. Correlation analysis of plasma YAP level with stroke prognostic factors and post-stroke inflammation[J]. Journal of Capital Medical University, 2024, 45(6): 1071-1078.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.06.017

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I6/1071

References

［1］ Tian T, Wang L J, Xu J L, et al. Prediction of early neurological deterioration in acute ischemic stroke patients treated with intravenous thrombolysis［J］. J Cereb Blood Flow Metab, 2023, 43(12): 2049-2059.
［2］ Sobowale O A, Parry-Jones A R, Smith C J, et al. Interleukin-1 in stroke: from bench to bedside［J］. Stroke, 2016, 47(8): 2160-2167.
［3］ Zhao H P, Li F F, Huang Y Y, et al. Prognostic significance of plasma IL-2 and sIL-2Rα in patients with first-ever ischaemic stroke［J］. J Neuroinflammation, 2020, 17(1): 237.
［4］ Pawluk H, Kołodziejska R, Grzes′k G, et al. Selected mediators of inflammation in patients with acute ischemic stroke［J］. Int J Mol Sci, 2022, 23(18): 10614.
［5］ Qin C, Yang S, Chu Y H, et al. Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions［J］. Signal Transduct Target Ther, 2022, 7(1): 215.
［6］ Gong S S, Ma H F, Zheng F, et al. Inhibiting YAP in endothelial cells from entering the nucleus attenuates Blood-Brain barrier damage during Ischemia-Reperfusion injury［J］. Front Pharmacol, 2021, 12: 777680.
［7］ Gong P, Zhang Z, Zou C L, et al. Hippo/YAP signaling pathway mitigates blood-brain barrier disruption after cerebral ischemia/reperfusion injury［J］. Behav Brain Res, 2019, 356: 8-17.
［8］ Li W Y, Xu P F, Kong L Q, et al. Elabela-APJ axis mediates angiogenesis via YAP/TAZ pathway in cerebral ischemia/reperfusion injury［J］. Transl Res, 2023, 257: 78-92.
［9］ Zhao S Q, Yin J, Zhou L J, et al. Hippo/MST1 signaling mediates microglial activation following acute cerebral ischemia-reperfusion injury［J］. Brain Behav Immun, 2016, 55: 236-248.
［10］中华医学会神经病学分会. 中华医学会神经病学分会脑血管病学组.中国急性缺血性卒中诊治指南2023［J］. 中华神经科杂志, 2024, 57(6): 523-559.
［11］ Zhong Z, Jiao Z, Yu F X. The hippo signaling pathway in development and regeneration［J］. Cell Rep, 2024, 43(3): 38457338.
［12］ Liu L, Li J, Wang Y L, et al. Effects of Panax notoginseng saponins on alleviating low shear induced endothelial inflammation and thrombosis via piezo1 signalling［J］. J Ethnopharmacol, 2024, 335: 118639.
［13］ Yang Y, Wang D Y, Zhang C X, et al. Piezo1 mediates endothelial atherogenic inflammatory responses via regulation of YAP/TAZ activation［J］. Hum Cell, 2022, 35(1): 51-62.
［14］ Wang L, Luo J Y, Li B C, et al. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow［J］. Nature, 2016, 540(7634): 579-582.
［15］ Xu X T, Zhang C W, Jiang J X, et al. Effect of TDP43-CTFs35 on brain endothelial cell functions in cerebral ischemic injury［J］. Mol Neurobiol, 2022, 59(7): 4593-4611.
［16］ Medina-Dols A, Cañellas G, Capó T, et al. Role of PATJ in stroke prognosis by modulating endothelial to mesenchymal transition through the Hippo/Notch/PI3K axis［J］. Cell Death Discov, 2024, 10(1): 85.
［17］ Chen R D, Qian L, Fu J, et al. Downregulation of Preso protects against ischemic/reperfusion-mediated neuronal injury through regulating PSD95-nNOS/YAP pathways［J］. Neurochem Int, 2023, 169: 105586.
［18］ Gong P, Zou Y C, Zhang W, et al. The neuroprotective effects of Insulin-Like Growth Factor 1 via the Hippo/YAP signaling pathway are mediated by the PI3K/AKT cascade following cerebral ischemia/reperfusion injury［J］. Brain Res Bull, 2021, 177: 373-387.
［19］ Zhang X L, Du W H, Qian S X, et al. Glial growth factor 2 treatment alleviates ischemia and reperfusion-damaged integrity of the blood-brain barrier through decreasing Mfsd2a/caveolin-1-mediated transcellular and Pdlim5/YAP/TAZ-mediated paracellular permeability［J］. Acta Pharmacol Sin, 2024, 45(11): 2241-2252.
［20］ Mia M M, Singh M K. Emerging roles of the Hippo signaling pathway in modulating immune response and inflammation-driven tissue repair and remodeling［J］. FEBS J, 2022, 289(14): 4061-4081.
［21］ Chen L B, Jin X T, Ma J, et al. YAP at the progression of inflammation［J］. Front Cell Dev Biol, 2023, 11: 1204033.
［22］ Iadecola C, Buckwalter M S, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential［J］. J Clin Invest, 2020, 130(6): 2777-2788.
［23］ Wang Q, Xu S F, Wang B, et al. Chemokine receptor 7 mediates miRNA-182 to regulate cerebral ischemia/reperfusion injury in rats［J］. CNS Neurosci Ther, 2023, 29(2): 712-726.
［24］ Huang Z H, Wang Y, Hu G Q, et al. YAP is a critical inducer of SOCS3, preventing reactive astrogliosis［J］. Cereb Cortex, 2016, 26(5): 2299-2310.
［25］ Yang Y, Gong Z Y, Wang Z Y. Yes-associated protein reduces neuroinflammation through upregulation of Sirt3 and inhibition of JNK signaling pathway［J］. J Recept Signal Transduct Res, 2019, 39(5/6): 479-487.
［26］ Gong P Y, Liu Y K, Gong Y C, et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke［J］. J Neuroinflammation, 2021, 18(1): 51.
［27］ Zhu H, Hu S P, Li Y T, et al. Interleukins and ischemic stroke［J］. Front Immunol, 2022, 13: 828447.
［28］ Shi L G, Sun Z Y, Su W, et al. Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke［J］. Immunity, 2021, 54(7): 1527-1542.e8.
［29］ Li X M, Lin S Y, Chen X L, et al. The prognostic value of serum cytokines in patients with acute ischemic stroke［J］. Aging Dis, 2019, 10(3): 544-556.
［30］ Cui Y, Wang X H, Zhao Y, et al. Association of serum biomarkers with early neurologic improvement after intravenous thrombolysis in ischemic stroke［J］. PLoS One, 2022, 17(10): e0277020.
［31］ de Bilbao F, Arsenijevic D, Moll T, et al. in vivo over-expression of interleukin-10 increases resistance to focal brain ischemia in mice［J］. J Neurochem, 2009, 110(1): 12-22.
［32］ Chang L T, Yuen C M, Liou C W, et al. Link between interleukin-10 level and outcome after ischemic stroke［J］. Neuroimmunomodulation, 2010, 17(4): 223-228.
［33］ Liu X L, Du J Z, Zhou Y M, et al. Interleukin-16 polymorphism is associated with an increased risk of ischemic stroke［J］. Mediators Inflamm, 2013, 2013: 564750.
［34］ Finisguerra V, Di Conza G, Di Matteo M, et al. Met is required for the recruitment of anti-tumoural neutrophils［J］. Nature, 2015, 522(7556): 349-353.
［35］ Zhu Z B, Xu T, Guo D X, et al. Serum hepatocyte growth factor is probably associated with 3-Month prognosis of acute ischemic stroke［J］. Stroke, 2018, 49(2): 377-383.

[1]	Li Xingmao, Li Xiu, Wang Ting, Zhao Xin, Wang Deyang, Shang Haiyan, Zhao Yongmei, Li Sen. Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes mellitus after acute ischemic stroke [J]. Journal of Capital Medical University, 2024, 45(6): 1029-1037.
[2]	Liang Fa, Wu Youxuan, Wang Xinyan, Jian Minyu, Liu Haiyang, Han Ruquan. Effects of emergency conversion to general anesthesia on neurological outcomes of patients with acute ischemic stroke undergoing mechanical thrombectomy [J]. Journal of Capital Medical University, 2023, 44(2): 237-243.